Process that drives prostate cancer metastasis uncovered

A novel function of the gene PLK1 (polo-like kinase 1) has been uncovered that helps prostate cancer cells metastasize (spread) to other parts of the body. This mechanism highlights new potential targets for cancer therapies and challenges the previous understanding of PLK1’s role in cancer growth and progression.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

Abstract OBJECTIVE: To prospectively evaluate short- to medium-term patient-reported lower urinary tract symptoms (LUTS) and their effect on health-related quality of life (HRQoL) using validated questionnaires in a large cohort of patients following robotic-assisted radical prostatectomy (RARP) for prostate cancer. MATERIALS AND METHODS: HRQoL and LUTS outcomes were prospectively assessed in 357 consecutive men undergoing RARP at a single center from 2012 to 2015 using the functional assessment of cancer therapy-prostate (FACT-P) and the international consultation on incontinence modular questionnaire-male L...
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
Two circulating tumor cell (CTC) assays can predict which men with advanced prostate cancer are unlikely to benefit from anti-androgen therapies, researchers said in a June 4 presentation at ASCO 2018.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news
Conclusions: This study demonstrated that the use of different targeting vectors for delivery of 225Ac alters the pharmacokinetics and suppliers of unbound 213Bi, to the kidneys. These properties are important for translation to clinical studies as in vivo imaging cannot distinguish between the intact 225Ac-labeled agent and the unbound 213Bi, resulting in an overestimation of the average radiation dose to kidneys and an underestimation of the average radiation dose to the supplying organ (blood and liver, respectively).
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Clinical Dosimetry Source Type: research
535Objectives: Targeted radionuclide therapy (TRT) has recently gained great momentum due to the promising results achieved in the treatment of neuroendocrine and prostate cancer. However, similar approaches elude breast cancer therapies given the lack of radiopharmaceuticals that effectively target breast cancer. Our goal is to develop a theranostic strategy that uses a novel alkylphosphocholine analog (NM600) labeled with 86Y for targeted PET imaging and 177Lu for TRT in a syngeneic murine model of breast cancer. Methods: NM600 was synthesized by conjugating 18-(p-aminophenyl)octadecyl phosphocholine to the chelator DOTA...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Preclinical Probes for Oncology II Source Type: research
Design and synthesis of functionalized piperazin-1yl-(E)-stilbenes as inhibitors of 17α-hydroxylase-C17,20-lyase (Cyp17). Bioorg Med Chem Lett. 2018 May 22;: Authors: Blass BE, Iyer P, Abou-Gharbia M, Childers WE, Gordon JC, Ramanjulu M, Morton G, Arumugam P, Boruwa J, Ellingboe J, Mitra S, Reddy Nimmareddy R, Paliwal S, Rajasekhar J, Shivakumar S, Srivastava P, Tangirala RS, Venkataramanaiah K, Bobbala R, Yanamandra M, Krishnakanth Reddy L Abstract The synthesis of steroid hormones is critical to human physiology and improper regulation of either the synthesis of these key molecules or activati...
Source: Bioorganic and Medicinal Chemistry Letters - Category: Chemistry Authors: Tags: Bioorg Med Chem Lett Source Type: research
Personalization of prostate cancer therapy through phosphoproteomics, Published online: 11 May 2018; doi:10.1038/s41585-018-0014-0Yang and colleagues discuss the clinical need and rationale for a phosphoproteomics approach to personalizing prostate cancer treatment. They describe current technologies, clinical findings, and challenges and strategies to realizing routine clinical application of phosphoproteomics.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.8b00152
Source: Molecular Pharmaceutics - Category: Drugs & Pharmacology Authors: Source Type: research
In conclusion, we identify montelukast may be used as a novel agent for the treatment of prostate cancer by decreasing HIF-1α protein translation. PMID: 29708817 [PubMed - as supplied by publisher]
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
In this study, PEGylated bilirubin-based nanoparticles (BRNPs) were chosen as an appropriate delivery carrier because of their ability to release drugs in response to TME-associated reactive oxygen species (ROS) through rapid particle disruption. As a model SMDC, ACUPA-SN38 was synthesized by linking the prostate membrane-specific antigen (PSMA)-targeting ligand, ACUPA, to the chemotherapeutic agent, SN38. ACUPA-SN38 was loaded into BRNPs using a film-formation and rehydration method. The resulting ACUPA-SN38@BRNPs exhibited ROS-mediated particle disruption and rapid release of the SMDC, resulting in greater cytotoxicity t...
Source: Biomacromolecules - Category: Biochemistry Authors: Tags: Biomacromolecules Source Type: research
This study focused to clarify the roles of Metadherin (MTDH) and miR-342-3p in prostate cancer. We identified that MTDH was up-regulated and miR-342-3p was down-regulated in the prostate tissues, and there is an inverse correlation between MTDH and miR-342-3p. Functional studies revealed that miR-342-3p directly targets MTDH via binding to the 3’untranslated regions (UTRs) in the prostate cancer cells. Moreover, we also found MTDH overexpression in DU145 and PC3 cells inhibited apoptosis. Subsequently, miR-342-3p has been revealed to reverse the MTDH effect on the cellular apoptosis in the further studies. Our result...
Source: Saudi Journal of Biological Sciences - Category: Biology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Prostate Cancer | Science